Value appropriation in hepatitis C

BACKGROUND: In 2015, the Swedish government in an unprecedented move decided to allocate 150 million € to provide funding for new drugs for hepatitis C. This was triggered by the introduction of the first second generation of direct-acting antivirals (DAAs) promising higher cure rates and reduced si...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindgren, Peter, Löfvendahl, Sofia, Brådvik, Gunnar, Weiland, Ola, Jönsson, Bengt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304061/
https://www.ncbi.nlm.nih.gov/pubmed/34855072
http://dx.doi.org/10.1007/s10198-021-01409-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304061/
https://www.ncbi.nlm.nih.gov/pubmed/34855072
http://dx.doi.org/10.1007/s10198-021-01409-7

Ejemplares similares